NCT07103980View on ClinicalTrials.gov

Inhaled Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Post-Infectious Cough: A Single-Center Randomized Controlled Clinical Trial

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 16, 2024

Primary Completion Date

July 30, 2025

Study Completion Date

December 30, 2025

Conditions
Post-Infectious Cough
Interventions
DRUG

Mesenchymal stem cell derived exosome nebulization combined with compound methoxyphenamine capsule

"Mesenchymal stem cell derived exosome nebulization (FITCELL 5ml nebulization QD) was combined with compound methoxyphenamine capsule ( Asmei 2 capsules oral TID) for cough treatment."

DRUG

Normal saline nebulization combined with the compound methoxyphenamine capsule

"Normal saline nebulization (0.9% sodium chloride 5ml nebulization QD) was combined with the compound methoxyphenamine capsule (Asmei 2 capsules oral TID) for cough treatment."

Trial Locations (1)

200000

RECRUITING

Shanghai changzheng hospital, Shanghai

All Listed Sponsors
lead

Shanghai Changzheng Hospital

OTHER